Verdence Capital Advisors LLC Buys New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Verdence Capital Advisors LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,220 shares of the medical equipment provider’s stock, valued at approximately $262,000.

Other large investors also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust lifted its holdings in Lantheus by 36.6% during the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 156 shares in the last quarter. RFG Advisory LLC lifted its holdings in Lantheus by 4.4% during the third quarter. RFG Advisory LLC now owns 3,940 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 167 shares in the last quarter. Prosperity Financial Group Inc. lifted its holdings in Lantheus by 6.2% during the third quarter. Prosperity Financial Group Inc. now owns 2,967 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 173 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in Lantheus by 3.1% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider’s stock valued at $432,000 after purchasing an additional 188 shares in the last quarter. Finally, Covestor Ltd lifted its holdings in Lantheus by 62.7% during the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 203 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Price Performance

Lantheus stock opened at $64.41 on Wednesday. The company has a market cap of $4.42 billion, a price-to-earnings ratio of 13.88 and a beta of 0.53. The firm’s fifty day moving average is $60.94 and its 200 day moving average is $62.78. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $100.85.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. The company had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 5.72 EPS for the current fiscal year.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were acquired at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold a total of 94,545 shares of company stock valued at $6,169,936 over the last 90 days. 2.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on LNTH shares. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. JMP Securities reissued a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. B. Riley boosted their target price on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Finally, Truist Financial reissued a “buy” rating and issued a $82.00 target price (up previously from $80.00) on shares of Lantheus in a report on Monday, February 26th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $104.71.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.